Business
Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference in Boston. TD Cowen 45th Annual Health Care Conference, March 3-5
About this update from Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will participate in a fireside chat at the TD Cowen 45 th Annual Health Care Conference in Boston. TD Cowen 45 th Annual Health Care Conference, March 3-5, 2025 Event details: Date: Monday, March 3, 2025 Time: 2:30 pm ET Location: Boston, MA Participants may access a live webcast of the event by clicking the link here . The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at www.verrica.com . A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event. About Verrica Pharmaceuticals Inc. Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. Verrica’s product YCANTH (VP-102) (cantharidin), is the first and only commercially available treatment approved by the FDA to treat adult and pediatric patients two years of age and older with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. YCANTH (VP-102) is also in development to treat common warts and external genital warts, two of the largest remaining unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for non-melanoma skin cancers including basal cell carcinoma and squamous cell carcinoma. For more information, visit www.verrica.com . FOR MORE INFORMATION, PLEASE CONTACT: Investors: John J Kirby Interim Chief Financial Officer [email protected] Kevin Gardner LifeSci Advisors [email protected] Chris Calabrese LifeSci Advisors [email protected]
View stock analysis, news, and events for Verrica Pharmaceuticals Inc.